Levels of acute inflammatory biomarkers in advanced prostate cancer patients with α 2-macroglobulin deficiency

International Journal of Oncology

Volumn 39, Issue 6, 2011, Pages 1553-1558

  Kanoh, Yuhsaku ^a   Ohtani, Hideki ^a   Egawa, Shin ^b   Baba, Shiro ^a   Akahoshi, Tohru ^a  

^a KITASATO UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

1 acid glycoprotein; 1 antitrypsin; 2 macroglobulin; C reactive protein; Ceruloplasmin; Interleukin 6; Prostate specific antigen; Serum amyloid A

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CERULOPLASMIN; INTERLEUKIN 6; OROSOMUCOID; RECOMBINANT INTERLEUKIN 6; SERUM AMYLOID A;

ADULT; AGED; ALPHA 2 MACROGLOBULIN DEFICIENCY; ARTICLE; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; WESTERN BLOTTING;

AGED; ALPHA 1-ANTICHYMOTRYPSIN; ALPHA-MACROGLOBULINS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CERULOPLASMIN; DISEASE PROGRESSION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASM STAGING; OROSOMUCOID; PROSTATIC NEOPLASMS; SERUM AMYLOID A PROTEIN;

EID: 80054801266     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1185     Document Type: Article

References (27)

1. 2-macroglobulin as a carrier protein for IL-6. J Immunol 142: 148-152, 1989.
2. 2-macroglobulin as a growth hormone-binding protein in human blood. J Clin Endocrinol Metab 80: 585-590, 1995.
3. Ohtani H, Saito M and Koshiba K: Alpha-2-macroglobulin deficiency in patients with advanced prostate cancer. Oncology 42: 341-344, 1985. (Pubitemid 16213235)
4. 2- macroglobulin deficiency in association with cancer metastasis. Jap J Clin Immun 20: 30-43, 1997.
5. dos Anjos BL and Grotto HZ: Evaluation of C-reactive protein and serum amyloid A in the detection of inflammatory and infectious disease in children. Clin Chem Lab Med 48: 493-499, 2010.
6. Kanoh Y, Ohara T and Akahoshi T: Acute inflammatory biomarkers in cerebrospinal fluid as indicator of blood cerebrospinal fluid barrier damage in Japanese subjects with infectious meningitis. Clin Lab 57: 37-46, 2011.
7. Fujiwara H, Suchi K, Okamura H, Umehara S, Toda M, Shiozaki A, Kubota T, Ichikawa D, Okamoto K, Ochiai T, Kokuba Y, Sonoyama T and Otsuji E: Elevated serum CRP levels after indication chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer. J Surg Oncol 103: 62-68, 2011.
8. Yap SH, Moshage HJ, Hazenberg BP, Roelofs MH, Bijizet J, Limburg PC, Aarden LA and van Rijiswijk MH: Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta 19: 1091: 405-408, 1991.
9. Smith JW and McDonald TL: Production of serum amyloid A and C-reactive protein by HepG2 cells stimulated with combinations of cytokines or monocyte conditioned media: the effects of prednisolone. Clin Exp Immunol 90: 293-299, 1992.
10. Smith JW, Colombo JL and McDonald TL: Comparison of serum amyloid A and C-reactive protein as indicator of lung inflammation in corticosteroid treated and non-corticosteroid cystic fibrosis patients. J Clin Lab Anal 6: 219-224, 1992.
11. Spiessl B, Beahrs OH, Hermanek P, et al. (eds): International Union Against Cancer. TNM Atlas. 3rd edition. 2nd revision. Springer-Verlag, New York, pp241-250, 1992.
12. Ida N, Sakurai S, Hosaka T, Hosoi K, Matsuura Y and Kohase M: An enzymelinked immunosorbent assay for the measurement of human interleukin-6. J Immunol Meth 133: 279-284, 1990. (Pubitemid 20338905)
13. Laemmli KU: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
14. Kasprzyk M, Dyszkiewicz W, Zwarun D, Lesniewska K and Wiktorowicz K: The assessment of acute phase proteins as prognostic factors in patients surgically treated for non-small cell lung cancer. Peumonol Alergo Pol 76: 321-326, 2008.
15. Bataille R, Boccadoro M, Klein B, Durie and Pileri A: C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80: 733-737, 1992.
16. Firooz N, Albert D, Wallace D, Ishimori M, Berel D and Weisman M: High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematous. Lupus 20: 588-597, 2011.
17. Pierce BL, Ballard-Barbrash R, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A and Urich CM: Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27: 3437-3444, 2009.
18. Imazio M, Brucato A, Maestroni S, Cumetti D, Dominelli A, Natale G and Trinchero R: Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implication for the diagnosis, therapy, and prognosis of pericarditis. Circulation 213: 1092-1097, 2011.
19. Kablak-Ziembicka A, Przewlocki T, Sokolowski A, Tracz W and Podolec P: Carotid intima-media thickness, hs-CRP and TNF-αare independently associated with cardiovascular event risk in patients with atherosclerotic occlusive disease. Atherosclerosis 214: 185-190, 2011.
20. Cocco E, Bellone S, El-Sahwi K, Cargneluti M, Buza N, Tavassoli FA, Schwartz PE, Rutherford TJ, Pecoreli S and Santin AD: Serum amyloid A: a novel biomarker for endometrial cancer. Cancer 116: 843-851, 2010.
21. Sasazuki S, Inoue M, Sawada N, Iwasaki M, Shimazu T, Yamaji T and Tsugane S: Plasma levels of C-reactive protein and serum amyloid A and gastric cancer in a nested case-control study; Japan Public Health Center-based prospective study. Carcinogenesis 31: 712-718, 2010.
22. Mroczko B, Groblewska M, Gryko M, Kedra B and Szmitkowski M: Diagnostic usefulness of serum interleukin-6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab Anal 24: 256-261, 2010.
23. Kim DK, Oh SY, Kwon HC, Lee S, Kwon KA, Kim BG, Kim SG, Jang JS, Kim MC, Kim KH, Han JY and Kim HJ: Clinical significances of preoperative serum interleukin-6 and C-reactive protein in operable gastric cancer. BMC Cancer 9: 155, 2009.
24. Alexandrakis MG, Kyriakou D, Koutroubakis IE, Alexandraki R, Vlachonikolis IG and Eliopoulos GD: Assaying of tumor necrosis factor alpha, complement factors, and alpha-1-antitrypsin in the diagnosis of malignant serous effusions. Am J Clin Oncol 24: 562-565, 2001. (Pubitemid 33131415)
25. Yildirim A, Meral M, Kaynar H, Polat and Ucar EY: Relationship between serum levels of some acute-phase proteins and stage of disease and performance status in patients with lung cancer. Med Sci Monit 13: 195-200, 2007.
26. Fotiou K, Vaiopoulos G, Liakos K, Giannopoulos A, Mandalenaki K, Marinos G, Koritsiadis G, Sourdis J, Konstantinidou E and Konstantopoulos K: Serum ceruloplasmin as a marker in prostate cancer. Mineral Urol Nefrol 59: 407-411, 2007. (Pubitemid 350247724)
27. Kasprzyk M, Dyszkiewicz W, Zwarun D, Szydik S, Lesniewska K and Krzyzanowski K: The quantitative elevation of the serum acute phase proteins (APP) of patients undergoing a curative resection for non-small cell lung cancer (NSCLC). Przegl Lek 63: 936-940, 2006.